Status:
TERMINATED
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
Eligibility Criteria
Inclusion
- Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)
- Smoking history of at least 10 pack-years
Exclusion
- Any significant co-morbid disease
- Use of any maintenance therapy except short acting bronchodilators
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
324 Patients enrolled
Trial Details
Trial ID
NCT00263874
Start Date
November 1 2005
End Date
September 1 2006
Last Update
July 23 2007
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina, C1904AGP
2
Pfizer Investigational Site
Vicente López, Buenos Aires, Argentina, 1602
3
Pfizer Investigational Site
Rosario, Santa Fé, Argentina, 2000
4
Pfizer Investigational Site
Buenos Aires, Argentina, 1426